Core Scientific (CORZ) Equity Average (2021 - 2026)

Core Scientific has disclosed Equity Average across 6 years of filings, most recently posting -$1.1 billion for Q1 2026.

• Equity Average for Q1 2026 came in at -$1.1 billion, down 81.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.1 billion (down 81.2% YoY), and the FY2025 annual result was -$952.9 million, down 23.75% from the prior year.
• Equity Average came in at -$1.1 billion for Q1 2026 at Core Scientific, down from -$1.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.2 billion in Q1 2022 to a low of -$1.2 billion in Q3 2025.
• The 5-year median for Equity Average is -$507.8 million (2023), against an average of -$445.1 million.
• Across the five-year window, Equity Average surged 1224.13% in 2022 and sank 265.72% in 2023, its largest moves.
• Core Scientific's Equity Average stood at -$168.2 million in 2022, then slumped by 202.0% to -$507.8 million in 2023, then tumbled by 74.24% to -$884.9 million in 2024, then decreased by 25.18% to -$1.1 billion in 2025, then retreated by 2.39% to -$1.1 billion in 2026.
• The last three Equity Average figures came in at -$1.1 billion (Q1 2026), -$1.1 billion (Q4 2025), and -$1.2 billion (Q3 2025), per Business Quant data.